Skip to content
HowShorted

Fulgent Genetics, Inc. short interest in 2023

In 2023, Fulgent Genetics, Inc.'s disclosed short interest ran from 3.98% of shares outstanding on 13 Jan 2023 to 1.86% on 29 Dec 2023, a change of -2.12 percentage points. The year's high was 3.98% on 13 Jan 2023 and its low 1.83% on 15 Aug 2023, averaging 2.60% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.68 days on 28 Apr 2023. Full history: Fulgent Genetics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Fulgent Genetics, Inc. in 2023

2023 in figures

Start of year
3.98% (13 Jan 2023)
End of year
1.86% (29 Dec 2023)
Change
-2.12 pp
High
3.98% (13 Jan 2023)
Low
1.83% (15 Aug 2023)
Average
2.60%
Highest days to cover
5.68 (28 Apr 2023)
SEC filings marked
8

Every report in 2023

Fulgent Genetics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20233.98%4.65
31 Jan 20233.05%5.33
15 Feb 20232.91%4.50
28 Feb 20233.09%4.6310-K filed, results (8-K)
15 Mar 20233.90%4.20
31 Mar 20232.89%2.70
14 Apr 20232.53%5.20
28 Apr 20232.56%5.68
15 May 20232.73%3.3310-Q filed, results (8-K)
31 May 20232.52%2.83
15 Jun 20232.25%3.02
30 Jun 20232.12%2.90
14 Jul 20232.26%4.80
31 Jul 20232.06%5.02
15 Aug 20231.83%1.8210-Q filed, results (8-K)
31 Aug 20232.00%2.34
15 Sep 20231.84%2.63
29 Sep 20232.75%3.62
13 Oct 20232.86%3.63
31 Oct 20233.02%3.45
15 Nov 20233.14%3.7610-Q filed, results (8-K)
30 Nov 20232.09%4.35
15 Dec 20232.19%2.51
29 Dec 20231.86%2.62

See also: Fulgent Genetics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.